Investigation of <i>Sheng Mai Yin</i> in the treatment of anthracycline-induced frequent premature ventricular contractions in cancer patients: study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial.

ABSTRACT:

Introduction

Anthracycline-induced cardiotoxicity is a major concern in cancer treatment, as it can lead to various arrhythmias, with frequent premature ventricular contractions (PVCs) being one of the most common types. Sheng Mai Yin (SMY), a widely used Chinese herbal compound in China, has shown potential in treating anthracycline-induced cardiac dysfunction and arrhythmias. However, the evidence supporting its efficacy is limited due to methodological flaws in prior studies. Therefore, high-quality trials are essential to rigorously evaluate the efficacy and safety of SMY.

Methods

This multicenter, randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of SMY in treating frequent PVCs induced by anthracycline chemotherapy. A total o

SUBMITTER: Yang Q 

PROVIDER: S-EPMC12682750 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature